Immix Biopharma (NASDAQ:IMMX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09, Zacks reports.
Immix Biopharma Stock Performance
NASDAQ IMMX traded down $0.01 on Friday, reaching $1.70. The company's stock had a trading volume of 24,157 shares, compared to its average volume of 133,209. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $3.13. The firm's 50 day moving average is $1.84 and its two-hundred day moving average is $1.86. The stock has a market cap of $46.76 million, a PE ratio of -2.00 and a beta of 0.26.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Immix Biopharma in a research report on Monday, February 10th.
Get Our Latest Analysis on Immix Biopharma
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
